# Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

> **NCT07724457** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 271 (estimated)

## Conditions studied

- Recurrent Burkitt Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Refractory Burkitt Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Glofitamab
- **DRUG:** Ifosfamide
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Obinutuzumab
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Rituximab and Hyaluronidase Human
- **OTHER:** Survey Administration
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT07724457
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2033-11-01
- **Final completion:** 2033-11-01
- **Target enrollment:** 271 (ESTIMATED)
- **Last updated:** 2026-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724457, "Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07724457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*